Clinical Study Report

Sponsor:	**Hermal/BHI**
Study no.:	**250512BS / H 527 000 - 0518**
EudraCT-No.	**2005-004331-22**
Title:	**Determination of dermal tolerability of topical formulations on intact skin following repetitive non-occlusive application on intact skin during a 21 day treatment period**
Study preparation:	**Study preparations:** 1) Mometasone cream (0.1 % mometasone- furoate) 2) Active ingredient-free vehicle to mometasone cream 3) Mometasone ointment (0.1 % mometasone-fuorate) 4) Active ingredient-free vehicle to mometasone ointment **Negative control:** 0.9 % sodium chloride (NaCl) in water
Clinical phase:	**I**
Description:	The study was double-blind for the study preparations and observer-blind for the control with random assignment of the treatments to the test fields in 33 male or female subjects with healthy skin to get at least 30 evaluable cases. All subjects received all treatments. Altogether five test fields on the back were examined. The test fields were treated once daily during a 21 day treatment period (18 treatments). Applications were performed from Mondays to Saturdays. On Sundays no applications were performed. Clinical assessment of the test fields was performed on study days 2 to 6, 8 to 13, 15 to 20 and on study day 22.
Principal Investigator:	[redacted] bioskin Institute for Dermatological Research and Development GmbH Poppenbuetteler Bogen 25, D-22399 Hamburg, Germany
Clinical Trial Manager:	[redacted] Hermal/BHI Scholtzstraße 3, D-21465 Reinbek, Germany
GCP Compliance:	yes
Study dates:	January 23, 2006 to February 13, 2006
Date of Report:	June 20, 2006

1. Kopie Reg [FG]
2. " MSA/DS

2. Synopsis

Name of Company: **Hermal/BHI**	Individual Study Table Referring to Part of the Dossier	*(For National Authority Use Only)*
Name of Finished Product: n.a.	Volume: Page:	
Name of Active Ingredient: mometasone-furoate		

Title of Study:
Determination of dermal tolerability of topical formulations on intact skin following repetitive non-occlusive application on intact skin during a 21 day treatment period

Investigator(s):
[redacted]

Study center(s):
bioskin Institute for Dermatological Research and Development GmbH, Hamburg, Germany

Publication (reference):
Not applicable to this study

Studied period (years):	Phase of development:
2006	I

Objectives:
Nonspecific, local irritating reactions of the study preparations were evaluated on intact skin in subjects with healthy skin

Methodology:
Application of approximately 50 µl of study preparations and control to test fields with intact skin once daily during a 21 day treatment period (18 treatments), applications were performed daily from Mondays to Saturdays, on Sundays no application was performed, test fields were covered with a breathable membrane. Dermal reactions were clinically assessed using a score prior to renewed application on study days 2 - 21 and on study day 22

Number of subjects (planned and analyzed):
Thirty-three male or female volunteers were included in the study. There was one drop out. Thirty-two subjects were included in the analysis.

Diagnosis and main criteria for inclusion:
Subjects with healthy skin in the area of the test fields on which reddening could be easily recognized, aged 18 to 50 years.

Test product(s), dose and mode of administration, batch number:

Study preparations:

1. Mometasone cream (0.1 % mometasone-furoate) batch no.: 541KK01
2. Active ingredient-free vehicle to mometasone cream batch no.: 541KK01
3. Mometasone ointment (0.1 % mometasone-fuorate) batch no.: 542KK01
4. Active ingredient-free vehicle to mometasone ointment batch no: 542KK01

topical application of approximately 50 µl formulation per test field (2.0 cm^2) once daily.
Approx. 50 µg/day mometasone-furoate, total dosage: approx. 0.9 mg mometasone-furoate

Duration of treatment:
21 days (18 treatments)

(continued...)

2. Synopsis (continued)

Name of Company: **Hermal/BHI**	Individual Study Table Referring to Part of the Dossier	*(For National Authority Use Only)*
Name of Finished Product: n.a.	Volume:	
Name of Active Ingredient: mometasone-furoate	Page:	

Reference therapy or controls, dose and mode of administration, batch number:

Negative control:

0.9 % sodium chloride (NaCl) in water, batch no: 5411C12

topical application of approximately 50 µl formulation on one test field (2.0 cm²) once daily.

Duration of treatment:

21 days(18 treatments)

Criteria for evaluation:

Efficacy: Nonspecific, local irritating reactions of the study preparations were evaluated on intact skin in subjects with healthy skin.

Safety:

Medical history, screening and final clinical examination, recording of adverse events.

Statistical Methods:

Statistical analysis

For each study preparation the variable erythema was to be listed using descriptive statistics (number of valid cases, frequencies, median, minimum, maximum, first and third quartiles). Tables were to be provided for each of the 18 assessment days.

For each assessment day the following parameters were to be calculated for the study variable:

1. number of dermal reactions (score value > 0): used to describe in how many cases a reaction was observed
2. score sum (sum of the score values): reflects the extent of dermal reactions on each day
3. frequency of scores (number of occurrences for each score value): expresses the number of occurrences of each score value

In addition, a total score sum reflecting the scope of dermal reactions over all study days was to be calculated.

The assessment of the irritant potential of each study preparation was based on the frequency of the individual scores, especially with respect to the number of subjects showing cumulative reactions, that is increasing scores over the study period.

Inferential statistical methods were not used, i.e. no p-value or confidence interval calculation.

All individual data and results are given including those of dropouts/withdrawals. In the event of discontinuation of a study preparation due to a dermal reaction (erythema score > 2), the score assigned at the test point at discontinuation was to be carried forward for all remaining assessment periods (LOCF: last observation carried forward).

Since there were no erythematous reactions observed during this study, no summary tables or figures were created for the clinical assessment of erythema.

2. Synopsis (continued)

Name of Company: **Hermal/BHI**	Individual Study Table Referring to Part of the Dossier	*(For National Authority Use Only)*
Name of Finished Product: n.a.	Volume:	
Name of Active Ingredient: mometasone-furoate	Page:	

Summary, conclusions:

Efficacy results:

The dermal tolerability of both Mometasone formulations as well as their vehicles was very good under the conditions of this study. There were no erythematous reactions observed neither after treatment with the study preparations Mometasone cream and Mometasone ointment containing 0.1 % mometasone-furoate nor for their corresponding vehicle during the 21day treatment period.

Safety results:

Only six adverse events of mild intensity occurred during the study, the relationship to the study product was classified as unlikely. There were no other relevant observations related to safety in this study.

Conclusion:

The purpose of this study was to evaluate the nonspecific, local irritating reactions of the study preparations on intact skin in subjects with healthy skin. The dermal tolerability of Mometasone cream and ointment (0.1 % mometasone-furoate) as well as their vehicles was very good under the conditions of this study. There were no erythematous reactions observed during the 21 day treatment period.

There were no relevant observations related to safety in this study.

Date of the report: June 20, 2006